Tagged with IT

Switzerland Sandoz Switzerland’s Jan Tangermann highlights the importance of the Swiss affiliate to the global group and how it was able to provide sustainable and reliable access to critical and essential medicines during the COVID-19 pandemic. Tangermann also makes a compelling case against the implementation of a reference pricing system and…

Switzerland Thomas Bohn outlines how the life sciences industry in Western Switzerland has continued to perform well despite the COVID-19 pandemic, highlights some of the key recent investments in the Greater Geneva Bern area (GGBa), and gives an overview of what the region has to offer global companies across the life…

Switzerland Marcel Plattner, president of Swiss industry association vips discusses pricing, market access and innovation, as well as the continuing attractiveness of Switzerland as a pharmaceutical investment destination.   Attractive conditions must be maintained both for the large pharmaceutical companies – which are well established in Switzerland, but for which the…

Switzerland Pierrre Morneau of Takeda Switzerland explains the therapeutic areas at the core of the company, equitable access, the Swiss framework for rare diseases, and the major challenges he is dealing with today.   The environment is shifting at a more rapid speed than ever before. Past paradigms are obsolete Having…

Global Dr Ann Aerts, head of the Novartis Foundation, highlights how the COVID-19 crisis has thrust artificial intelligence in healthcare into the limelight, and makes three bold predictions for the future of the field, especially in emerging countries.   As a true believer in the power of technology to transform health,…

Switzerland Alan Knox of Primex Pharmaceuticals explains how the COVID-19 pandemic has thrust the anaesthesia field back into the global spotlight, the benefits of incremental innovation in anaesthesia, and why having a Swiss headquarters is advantageous.   Up until COVID-19, Anaesthesia was incredibly underrepresented and undervalued as a therapeutic class. However,…

China While cell and gene therapies are all the rage now, a little known fact is that the world’s first approved gene therapy actually came from a Chinese company – in 2003! Gendicine® was a gene therapy for the treatment of haemophilia B. While China mostly lost the advantage of that…

Turkey When Abdi Ibrahim acquired a 28.5 percent stake in Swiss biotech OM Pharma in September 2020, it represented a historic moment for Turkey’s pharma industry; the first time a Turkish firm had ever taken part in the management of a European company.   With this partnership agreement, the long trend…

Global Merck Healthcare’s newly appointed Global Head of Business innovation, Renée C. Amundsen, highlights the numerous opportunities for change management that the COVID-19 pandemic has thrown up, why company-HCP interaction might never be the same again, and shares some pearls of wisdom for other women in pharma.   I see Merck’s…

USA Brent Ragans of Ferring Pharmaceuticals US discusses the effects of the COVID-19 pandemic on the company’s operations, their footprint in reproductive health and Crohn’s Disease, virtual product launches and digitalisation, and the battle for talent in the competitive US market.   US physicians have learned that, out of necessity, they…

Switzerland Novo Nordisk Switzerland’s Mads Stoustrup introduces the affiliate’s remarkable process on bringing innovative diabetes and obesity treatments to market in the past four years, the road still to travel to ensure better outcomes for chronic disease patients in Switzerland, and the leadership he hopes to cultivate during the COVID-19 pandemic…

Switzerland In a wide-ranging interview, Henrik Asmussen outlines his priorities for Amgen’s important Swiss affiliate, market access and pricing challenges, the company’s exciting pipeline, and what makes Amgen Switzerland a great place to work.   I was told when I came that Switzerland is a safe haven with easy access. What…